SAN DIEGO, Oct. 12, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present new clinical data on ImmunoPulse® IL-12 (intratumoral pIL-12 [tavokinogene telseplasmid or "tavo"] with electroporation), its lead program focused on oncology, at the upcoming 9th World Congress of Melanoma – A Joint Meeting with the Society for Melanoma Research (SMR). In addition, Chris Twitty, Ph.D., Executive Director of Clinical Science, gave an oral presentation at the 2nd Annual Biomarkers & Precision Medicine USA Congress earlier this week.

"We are excited to share updated data from our phase 2 clinical monotherapy trial with ImmunoPulse IL-12 in patients with stage III/IV melanoma," said Punit Dhillon, CEO and President at OncoSec. "These data, along with the emerging clinical data from the phase 2 combination study, further support the rationale for our global, open-label, registration directed phase 2b clinical trial, PISCES/KEYNOTE-695, which we anticipate reporting initial data in mid-2018."

9th World Congress of Melanoma – A Joint Meeting with the Society for Melanoma Research

Dr. Alain Algazi, Associate Professor, Department of Medicine (Hematology/Oncology), at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, will give an oral presentation contrasting monotherapy ImmunoPulse IL-12 to its combination with pembrolizumab. The presentation includes an assessment of clinical and immune biomarker data from the company's recently completed monotherapy phase 2 trial. The 9th World Congress of Melanoma – A Joint Meeting with the Society for Melanoma Research (SMR) is to be held on October 18-22, 2017, in Brisbane, Australia.

Details of the presentation are as follows:

Abstract Title: Clinical Immune Monitoring and Biomarker Data of pIL-12 Monotherapy Compared to pIL-12 with Pembrolizumab in Metastatic Melanoma Supports the Rationale for Combination Therapy (Abstract # FC05-3)

Session Title: Biology and Biomarkers  

Date and Time: October 19, 2017 at 3:30 PM – 3:40 PM

Location: Brisbane Convention & Exhibition Centre

Dr. Algazi will present new clinical and immune monitoring data from patients treated with ImmunoPulse IL-12, as a monotherapy (n=51 patients) versus the combination of ImmunoPulse IL-12 and the approved anti-PD-1 therapy pembrolizumab (n=22 patients) to better understand the mechanisms associated with each immunotherapy protocol.  In the 51 patients treated with ImmunoPulse IL-12 as monotherapy, an average of 33.5% best overall response rate (BORR) at 180 days by a modified "skin" RECIST was demonstrated, in addition to a favorable safety profile (no life threatening or grade 4 AE). In the combination trial of 22 patients treated to date, a 48% BORR was observed at 24 weeks. Biomarker analyses suggest ImmunoPulse IL-12 drives a cellular response leading to an inflamed tumor with an increased TIL frequency whether as a monotherapy or combined with pembrolizumab, converting "cold" tumors to "hot".

Further details on this presentation will be provided in upcoming Company communications. For more information about this conference, please visit: https://worldmelanoma2017.com

2nd Annual Biomarkers & Precision Medicine USA Congress

Chris Twitty, Ph.D., Executive Director of Clinical Science at OncoSec, gave an oral presentation entitled: "Interrogation of the tumor microenvironment and associated immunity in patients with melanoma" in addition to leading a panel discussion at the 2nd Annual Biomarkers & Precision Medicine USA Congress on October 10, 2017 at the Hilton San Diego Mission Valley Hotel in San Diego, CA. For more information, please visit: https://www.biomarkersusa-congress.com/.

About OncoSec Medical Incorporated:

OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse^®, for the treatment of cancer. ImmunoPulse is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or "tavo"). In Phase 1 and 2 clinical trials, ImmunoPulse^® IL-12 has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies. In addition to tavo, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform. For more information, please visit www.oncosec.com.

CONTACT:

Investor Relations 
OncoSec Medical Incorporated
855-662-6732
[email protected]

Media Relations 
OncoSec Medical Incorporated
855-662-6732

View original content with multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-updated-clinical-and-immune-biomarker-data-from-its-monotherapy-and-combination-therapy-studies-with-immunopulse-il-12-at-the-9th-world-congress-of-melanoma--a-joint-meeting-with-the-society-for-melanoma-resea-300535541.html

SOURCE OncoSec Medical Incorporated